New website, 5/14
May 2014—Quantimetrix launched its new website, quantimetrix.com. The website features fast, content-rich resources with a responsive design technology.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
GI panel submitted for 510(k) clearance, 5/14
May 2014—BioFire Diagnostics submitted the FilmArray Gastrointestinal Panel to the FDA for 510(k) clearance.
QML for connectivity, 5/14
May 2014—Telcor released a software driver for the Pathfast cardiac biomarker analyzer that allows the company’s QML to automatically interface results from the analyzer to a laboratory information system and electronic medical record system.
Lynch syndrome diagnostic tests, 5/14
May 2014—Quest Diagnostics is offering new pathology and blood tests for identifying and assessing an individual’s risk of Lynch syndrome.
Distribution agreement
May 2014—Copan Diagnostics announced an agreement with Thermo Fisher Scientific to distribute the Copan WASP, a walk-away specimen processor, in the United States.
Urine specimen stabilizer, 5/14
May 2014—The Vacuette Urine CCM Tube from Greiner Bio-One is an evacuated tube, which contains a stabilizer powder that keeps the urine sample stable up to 48 hours at 20°–25°C.
Siemens, NKF enter strategic alliance, 5/14
May 2014—Siemens Healthcare and the National Kidney Foundation entered into a strategic alliance to increase awareness of the importance of albumin-to-creatinine ratio testing in high-risk individuals, with the goal of improving diagnosis and identifying kidney disease early in its course. Siemens and NKF will also help put the new clinical recommendations into practice.
Vidas C. difficile GDH, 5/14
May 2014—BioMérieux launched its Vidas C. difficile GDH for automated detection of GDH, a specific enzyme produced by C. difficile. Vidas C. difficile GDH is the first automated immunoassay cleared by the Food and Drug Administration.
Bone marrow tissue stain, 5/14
May 2014—Dako added the Jenner-Wright Giemsa stain to its Artisan Link portfolio of automated stains. The stain is designed to provide clear differentiation and detail of the hematopoietic cells in bone marrow tissue samples for the diagnosis of cancer, aplastic anemia, and myelofibrosis.
Hsp70 ELISA kit, 5/14
May 2014—Enzo Life Sciences now offers the Amp’d HSP70 High Sensitivity ELISA Kit for detecting both baseline and upregulated levels of Hsp70 (Hsp72).